title: BeEAM conditioning with bendamustine-replacing BCNU before autologous transplantation is safe and effective in lymphoma patients.
abstract: BEAM with BCNU is commonly used for conditioning treatment followed by autologous stem cell transplantation (ASCT). However, pulmonary toxicity and availability issues associated with BCNU prompted us to evaluate bendamustine-replacing BCNU (BeEAM). We analyzed 39 lymphoma patients receiving BeEAM conditioning with 200 mg/m2bendamustine at days -7 and -6. The median duration until neutrophil recovery was 11 days, and 15 days for platelet recovery (>20 g/L). The most common grade 3/4 non-hematologic toxicities comprised mucosal side effects (27 pts.). Pulmonary toxicity was observed in one patient (2.5%), and one patient died of septic complications. The CR rate increased from 33% to 74% 100 days after ASCT. After a median follow-up of 18.5 months, progression and death each occurred in 11 patients (28%). Median progression-free and overall survival at 2 years were 69% and 72%. Our data suggest that BeEAM conditioning using bendamustine is safe and results in promising survival rates.
authors.affiliation: Department of Medical Oncology, University Hospital Bern, 3010, Berne, Switzerland.
authors.forename: Stefanie
authors.initials: S
authors.lastname: Gilli
authors.affiliation: Department of Medical Oncology, University Hospital Bern, 3010, Berne, Switzerland.
authors.forename: Urban
authors.initials: U
authors.lastname: Novak
authors.affiliation: Department of Hematology, University Hospital Bern, Berne, Switzerland.
authors.forename: Behrouz Mansouri
authors.initials: BM
authors.lastname: Taleghani
authors.affiliation: Department of Hematology, University Hospital Bern, Berne, Switzerland.
authors.forename: Gabriela M
authors.initials: GM
authors.lastname: Baerlocher
authors.affiliation: Department of Pediatric Hemato-Oncology, Inselspital, University Hospital Bern, Berne, Switzerland.
authors.forename: Kurt
authors.initials: K
authors.lastname: Leibundgut
authors.affiliation: Institute of Pathology, University of Bern, Berne, Switzerland.
authors.forename: Yara
authors.initials: Y
authors.lastname: Banz
authors.affiliation: Department of Oncology, Kantonsspital, Lucerne, Switzerland.
authors.forename: Thilo
authors.initials: T
authors.lastname: Zander
authors.affiliation: Department of Oncology, Kantonsspital, Fribourg, Switzerland.
authors.forename: Daniel
authors.initials: D
authors.lastname: Betticher
authors.affiliation: Department of Oncology, Kantonsspital, Solothurn, Switzerland.
authors.forename: Thomas
authors.initials: T
authors.lastname: Egger
authors.affiliation: Department of Oncology, Regionalspital, Thun, Switzerland.
authors.forename: Daniel
authors.initials: D
authors.lastname: Rauch
authors.affiliation: Department of Medical Oncology, University Hospital Bern, 3010, Berne, Switzerland. thomas.pabst@insel.ch.
authors.forename: Thomas
authors.initials: T
authors.lastname: Pabst
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage*; D000069461:Bendamustine Hydrochloride / Q000008:administration & dosage*; D002330:Carmustine / Q000008:administration & dosage*; D005260:Female; D005500:Follow-Up Studies; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods* / Q000401:mortality; D006801:Humans; D008223:Lymphoma / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D015996:Survival Rate / Q000639:trends; D019172:Transplantation Conditioning / Q000379:methods* / Q000401:mortality; D014182:Transplantation, Autologous / Q000379:methods / Q000401:mortality; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D018906:Antineoplastic Agents, Alkylating; D000069461:Bendamustine Hydrochloride; D002330:Carmustine
keywords: Autologous; BCNU; BeEAM; Beam; Bendamustine; Chemotherapy; High dose; Lymphoma; Prognosis; Stem cell; Survival; Transplantation